Dr. Patrick Grierson, MD
Medical Oncology (Medical Oncology Physician)
10 Barnes West Dr, Div Im Medical Oncology, Mob #2
Saint Louis, MO 63141
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 250
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Ohio State University College of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2017020379 -
Internal Medicine Physician
MO license 2017020379
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
- Christian Hospital Northeast Saint Louis, MO
- Parkland Health Center Farmington, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 27,594
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, oxaliplatin, 0.5 mg | 8,900 | 12 |
| Injection, fosaprepitant, 1 mg | 7,200 | 23 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 6,420 | 11 |
| Injection, pembrolizumab, 1 mg | 4,600 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,290 | 63 |
| Injection, palonosetron hcl, 25 mcg | 930 | 46 |
| Injection, leucovorin calcium, per 50 mg | 656 | 24 |
| Injection, fluorouracil, 500 mg | 512 | 26 |
| Injection, granisetron hydrochloride, 100 mcg | 460 | 28 |
| Injection of additional new drug or substance into vein | 238 | 75 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 139 |
| Dexamethasone Other prescribers in Saint Louis, MO | 134 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 110 |
| Gabapentin Other prescribers in Saint Louis, MO | 84 |
| Loperamide (loperamide hcl) Other prescribers in Saint Louis, MO | 67 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 62 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 60 |
| Potassium Chloride Other prescribers in Saint Louis, MO | 51 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Saint Louis, MO | 42 |
| Prednisone Other prescribers in Saint Louis, MO | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $137 in total to this clinician.
| Exelixis Inc. | $121 |
|---|---|
| Taiho Oncology, Inc. | $15.77 |
| Food and Beverage | $137 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,397,776 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatinbased chemotherapy or pembrolizumabcontaining combinations for HER2 gastrointestinal cancers
Pfizer Inc. - An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of N0112 in Human Leukocyte Antigen-C0802-Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Sol…
AstraZeneca Pharmaceuticals LP - A study of KK2269 in adult participants with solid tumors
Kyowa Kirin Co., Ltd - A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer
AstraZeneca Pharmaceuticals LP - A modular Phase I II Open label Dose Escalation and Dose Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD9793 a T cell engaging Antibody Targeting Glypican3 GPC3 in Adult Pa…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.